Skip to main content
Fig. 2 | BMC Gastroenterology

Fig. 2

From: Glepaglutide, a novel glucagon-like peptide-2 agonist, has anti-inflammatory and mucosal regenerative effects in an experimental model of inflammatory bowel disease in rats

Fig. 2

Small intestinal mass on day 7 and day 14 in naive Wistar rats administered glepaglutide. Glepaglutide was administered once daily (80 nmol/kg and 400 nmol/kg, SC). ***p < 0.001 vs vehicle controls, #p < 0.05, 80 nmol/kg vs 400 nmol/kg glepaglutide in two-way ANOVA, followed by a Tukey multiple comparisons test. Data shown are mean ± SEM. SC, subcutaneously; SEM, standard error of the mean

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us